FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market

Listen to an audio podcast of the February 13 2020 FDA Drug Safety Communicationrequesting the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market. Potential risk of cancer outweighs the benefits.

Source: FDA Center for Drug Evaluation and Research - What's New - February 19, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news